Literature DB >> 28401018

OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma.

Yining Lu1, Collin M Labak1, Neha Jain1, Ian J Purvis1, Maheedhara R Guda1, Sarah E Bach2, Andrew J Tsung3, Swapna Asuthkar1, Kiran K Velpula4.   

Abstract

Medulloblastoma is one of the most prevalent pediatric brain malignancies, accounting for approximately 20% of all primary CNS tumors in children under the age of 19. OTX2 is the member of a highly conserved family of bicoid-like homeodomain transcription factors responsible for the regulation of cerebellar development and of current investigational interest in the tumorigenesis of medulloblastoma. Recent studies have revealed that Group 3 and Group 4 medulloblastomas show marked overexpression of OTX2 with a concurrent amplification of the MYC and MYCN oncogenes, respectively, correlating with anaplasticity and unfavorable patient outcomes. More recent attempts at elucidating the mechanism of OTX2-driven oncogenesis at the cellular level has also revealed that OTX2 may confer stem-cell like properties to tumor cells via epigenetic regulation. The review seeks to define the interaction pathways and binding partners involved in OTX2 function, its usefulness as a molecular marker for risk stratification and prognosis, and the mechanism by which it drives tumor maintenance. Additionally, it will preview unpublished data by our group highlighting the unanticipated involvement of OTX2 in the control of cellular metabolism.

Entities:  

Keywords:  MYC; OTX2; cancer metabolism; histone modification; medulloblastoma

Year:  2017        PMID: 28401018      PMCID: PMC5385649     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  46 in total

1.  Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites.

Authors:  Birgit Czermin; Raffaella Melfi; Donna McCabe; Volker Seitz; Axel Imhof; Vincenzo Pirrotta
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

2.  UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development.

Authors:  Karl Agger; Paul A C Cloos; Jesper Christensen; Diego Pasini; Simon Rose; Juri Rappsilber; Irina Issaeva; Eli Canaani; Anna Elisabetta Salcini; Kristian Helin
Journal:  Nature       Date:  2007-08-22       Impact factor: 49.962

Review 3.  The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics.

Authors:  Vinit Krishna Srivastava; Josephine Nalbantoglu
Journal:  Cancer Biol Ther       Date:  2010-06-16       Impact factor: 4.742

4.  Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice.

Authors:  John Y H Kim; Aaron L Nelson; Sibel A Algon; Ondrea Graves; Lisa Marie Sturla; Liliana C Goumnerova; David H Rowitch; Rosalind A Segal; Scott L Pomeroy
Journal:  Dev Biol       Date:  2003-11-01       Impact factor: 3.582

5.  OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Authors:  Ren-Yuan Bai; Verena Staedtke; Hart G Lidov; Charles G Eberhart; Gregory J Riggins
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

6.  OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.

Authors:  Talitha de Haas; Esmeralda Oussoren; Wieslawa Grajkowska; Marta Perek-Polnik; Mara Popovic; Lorna Zadravec-Zaletel; Marzia Perera; Giorgio Corte; Oliver Wirths; Peter van Sluis; Torsten Pietsch; Dirk Troost; Frank Baas; Rogier Versteeg; Marcel Kool
Journal:  J Neuropathol Exp Neurol       Date:  2006-02       Impact factor: 3.685

7.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

8.  Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.

Authors:  Matthew Wortham; Genglin Jin; Julia Lailai Sun; Darell D Bigner; Yiping He; Hai Yan
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 9.  Medulloblastoma stem cells: Promising targets in medulloblastoma therapy.

Authors:  Guo-Hao Huang; Qing-Fu Xu; You-Hong Cui; Ningning Li; Xiu-Wu Bian; Sheng-Qing Lv
Journal:  Cancer Sci       Date:  2016-04-27       Impact factor: 6.716

10.  Su(z)2 antagonizes auto-repression of Myc in Drosophila, increasing Myc levels and subsequent trans-activation.

Authors:  Abid Khan; Wesley Shover; Julie M Goodliffe
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

View more
  8 in total

1.  Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1.

Authors:  Yang Zhao; Tiantian Li; Shuaiwei Tian; Wei Meng; Yi Sui; Jian Yang; Baocheng Wang; Zhuangzhuang Liang; Heng Zhao; Yipeng Han; Yujie Tang; Lei Zhang; Jie Ma
Journal:  Cancer Manag Res       Date:  2020-12-03       Impact factor: 3.989

Review 2.  Genetic Regulation of Vertebrate Forebrain Development by Homeobox Genes.

Authors:  Ryan F Leung; Ankita M George; Enola M Roussel; Maree C Faux; Jeffrey T Wigle; David D Eisenstat
Journal:  Front Neurosci       Date:  2022-04-25       Impact factor: 5.152

Review 3.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

4.  Multi-omics analysis of intertumoral heterogeneity within medulloblastoma uncharted-pathway subtypes.

Authors:  Zhicen Li; Yifan Wei; Yanqiu Shao; Lei Tang; Jian Gong
Journal:  Brain Tumor Pathol       Date:  2021-06-28       Impact factor: 3.298

Review 5.  Heterogeneity in retinoblastoma: a tale of molecules and models.

Authors:  Sonya Stenfelt; Maria K E Blixt; Charlotta All-Ericsson; Finn Hallböök; Henrik Boije
Journal:  Clin Transl Med       Date:  2017-11-09

6.  Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.

Authors:  Jiajia Wang; Yi Sui; Qifeng Li; Yang Zhao; Xiaoshu Dong; Jian Yang; Zhuangzhuang Liang; Yipeng Han; Yujie Tang; Jie Ma
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

Review 7.  Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders.

Authors:  Doodipala Samba Reddy; Hasara Nethma Abeygunaratne
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

8.  Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling.

Authors:  Francesca Nazio; Francesco Cecconi; Agnese Po; Luana Abballe; Claudio Ballabio; Francesca Diomedi Camassei; Matteo Bordi; Antonio Camera; Simona Caruso; Ignazio Caruana; Marco Pezzullo; Caterina Ferraina; Giacomo Milletti; Matteo Gianesello; Sofia Reddel; Carmen Dolores De Luca; Donatella Ceglie; Sara Marinelli; Silvia Campello; Elena Papaleo; Evelina Miele; Antonella Cacchione; Andrea Carai; Maria Vinci; Enrico Velardi; Biagio De Angelis; Luca Tiberi; Concetta Quintarelli; Angela Mastronuzzi; Elisabetta Ferretti; Franco Locatelli
Journal:  Acta Neuropathol       Date:  2021-07-24       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.